Photo from wikipedia
Anti‐IL‐17A IgG/κ monoclonal antibody CJM112 binds both IL‐17A and IL‐17AF. The purpose of this First‐in‐Human study was to assess CJM112 effects on safety and efficacy in patients with moderate to… Click to show full abstract
Anti‐IL‐17A IgG/κ monoclonal antibody CJM112 binds both IL‐17A and IL‐17AF. The purpose of this First‐in‐Human study was to assess CJM112 effects on safety and efficacy in patients with moderate to severe plaque psoriasis.
Keywords:
antibody cjm112;
anti 17a;
human study;
first human;
moderate severe;
monoclonal antibody
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the European Academy of Dermatology and Venereology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!